Taiwan Semiconductor Manufacturing Company Limited
TSM
BUY
Oct 26, 2026Neutral
Decision brief
TSM closed at $424.37 on October 26, 2026, up 1.40% from $418.51 and the second consecutive advance after the October 22 capitulation, but the recovery again came on light volume - 9.51 million shares, 0.83x the 20-day average of 11.45 million and 0.87x the 60-day average of 10.97 million - so the tape still lacks institutional confirmation. Macro improved materially: the fell 5.45% to 18.39, moving deeper inside the 15-20 Neutral band and further from the Risk-Off threshold, the S&P 500 gained 0.70%, the Nasdaq 0.82% and the Russell 2000 0.38% in a broad-based advance, and the 10-year Treasury yield eased to 4.986% from 4.988%, keeping multiple-compression pressure contained. The stock has now recovered 2.92% from the $412.35 October 22 close and printed a $428.85 intraday high that edged above the October 20 high of $428.21, a marginally higher high to pair with the higher low of $411.11 set on October 23. Fundamentals remain the strongest part of the case: 18.15x forward earnings on FY27 consensus of $23.38529 and 24.24x on FY26 of $17.50426, a of 0.7644 against 50.9% revenue growth and 68.7% earnings growth, a 65.85% gross margin, a 58.65% operating margin and a 41.85% . Estimate revisions stayed one-sided: FY27 is up 4.87% in seven days and 9.87% in ninety, FY26 up 2.76% and 4.85%, with zero downward revisions in any period and zero downgrades in 90 days, while Barclays ($670), Needham ($560) and DA Davidson ($500) all maintained or raised targets after the October 15 print. Technicals are improving at the margin but not in structure: (14) recovered to 44.60 from 41.46, the histogram narrowed for the fourth time in five sessions to -3.870 from -4.818, and rose to 86.88 million, yet the line at -5.965 is still at a series low, price remains 2.12% below the 50-day of $433.58 and 4.46% below the 20-day of $444.17, and is 38.7% below its October 5 peak of 141.65 million. Earnings quality is excellent but decelerating: seven consecutive supplied beats, yet the September quarter's 1.67% surprise was the narrowest of the seven against a 6.29% average, and sequential growth slowed to +6.73% from +23.5%. The article pool is stale (all dated September 29 and predating the October 15 print), so the freshest usable catalysts are the revision feed and the October 15-26 price action. The next scheduled event is January 14, 2027, 79 days out, leaving the 30-day window technically clean of scheduled binary risk. I raise the score to 73 from 71 and keep the overall BUY, hold the one-month view at HOLD because the bounce still lacks volume and the 50-day has not been reclaimed, and keep BUY for six months and STRONG BUY for one year. The lines that matter are $407.13 (the October 15 low) on the downside and the $433.58-$435.16 zone on the upside.
Decision
Live price
$437.21
Recommendation score
73%
73%
Confidence
65%
65%
Outlook by horizon
1M
HOLD
Near
6M
BUY
Mid
1Y
STRONG BUY
Long
Primary catalyst
The October 26 session is the single most market-moving item: TSM added 1.40% to $424.37 after October 23's 1.49% rebound, printed a $428.85 high that cleared the October 20 high of $428.21, and did so while the dropped 5.45% to 18.39 and the S&P 500, Nasdaq and Russell 2000 all advanced - the first broad-based risk-on tape in a week - yet total volume was only 9.51 million shares, 0.83x the 20-day average, so the move confirms a pause in AI-specific liquidation rather than a genuine institutional bid. The next real test is the $433.58 50-day on volume or a retest of $407.13; note that the article pool in this bundle is dated September 29 and predates the October 15 print by more than two weeks, so the freshest usable catalysts are the analyst actions in the revision feed and the October 15-26 price action rather than the article content.
Hold roughly half to two-thirds of normal weight and avoid leverage. The regime is still classified Neutral with the at 18.39, but 20-day realized volatility is 33.05%, the is 2.99% of price, and the intermediate trend remains broken with price 2.12% below the 50-day . The October 23-26 two-day recovery justifies holding rather than cutting further, but the 0.83x volume means it does not yet justify adding aggressively. Rebuild toward full weight on a daily close above $435.16 with above-average volume, or on a retest of $407.13 that holds on declining volume; a daily close below $407.13 should reduce exposure further toward the $390.20 200-day rather than averaging down. The unresolved conflict is explicit: fundamentals (18.15x FY27 earnings, 0.7644 , zero downward revisions, 31.4% median analyst upside) argue for owning it, while the tape ( line at a series low of -5.965 with the signal at -2.095, 38.7% below its October 5 peak, price below both the 20-day and 50-day ) argues for patience.
Thesis Snapshot
Why It Works
The strongest bull case is that fundamentals are accelerating into a falling price for the fourth time in four months, and that asymmetry rarely persists: FY27 consensus sits at $23.38529 versus $22.29861 a week ago (+4.87%) and $21.28402 ninety days ago (+9.87%), FY26 at $17.50426 versus $17.03445 (+2.76%), the current quarter at $5.1641 versus $5.04936, with zero downward revisions in any period over 30 days and a rating mix of 6 Strong Buy, 14 Buy and a single Hold with zero downgrades in 90 days. At $424.37 the stock trades at 18.15x FY27 earnings and 27.50x trailing with a 0.7644 against 50.9% revenue growth and 68.7% earnings growth, and the sell-side gap has widened: the LOWEST published target of $440 is 3.7% above spot while the $584.39 mean implies 37.7% upside, and analysts kept raising through both drawdowns - Barclays to $670, DA Davidson maintaining $500, Needham to $560, Stifel initiating at $515. The franchise is unharmed at nearly 73% foundry share, a 65.85% gross margin, a 41.85% and seven consecutive beats, the > > golden-cross stack is still intact with price 8.76% above the $390.20 200-day , and the October 23-26 sessions produced a higher low at $411.11 followed by a higher high at $428.85 while the fell 5.45% to 18.39 and the S&P 500 gained 0.70% - the first evidence in a week that the AI-specific liquidation has ended. Prior published targets also earned validation: the $406-$419 entry zone was tagged twice, on October 23 at $411.11 and again on October 26 at $417.72, giving patient buyers the intended fill.
What Breaks It
The strongest argument against owning TSM here is that the two-day bounce was a low-quality reflex off support, not a repair: October 26 ran on 9.51 million shares, 0.83x the 20-day average, following October 23's 9.48 million, immediately after a 16.48 million-share distribution day - so the up-day/down-day volume asymmetry that defines institutional selling has not been broken for even one session. Price remains 2.12% below the 50-day at $433.58 and 4.46% below the 20-day at $444.17, the October 21 rejection high of $435.16 has not been touched, and the close at $424.37 leaves the stock only $17.24 above the October 15 earnings low of $407.13. The momentum deterioration is severe on level: the line printed a fresh series low at -5.965 and the signal fell to -2.095, at 44.60 is still in bearish territory below 50, and at 86.88 million sits 38.7% below the October 5 peak of 141.65 million. The fundamental cushion is thinner than it looks: the September quarter beat by only 1.67% versus a 6.29% seven-quarter average, sequential growth decelerated to +6.73% from +23.5%, and the market has now sold the same good print twice. A credible short thesis is that AI demand normalizes while N2 yields, advanced-packaging utilization and returns on the roughly $29.44B capacity approval plus the $100B Arizona program disappoint, compressing margins and the multiple from a 27.50x trailing base, with HBM, hybrid-bonding, glass-substrate and cooling suppliers absorbing a growing share of value-chain economics. Macro is only temporarily friendly: the at 18.39 can re-spike as it did on October 22, the 10-year yield at 4.986% is only 16 basis points off the 5.146% spike, the GF Value of $363.95 sits 14.2% below spot so there is no model floor, the feed's EV, cash and FCF aggregates cannot be reconciled to the $2.20T market cap, and short interest at just 0.63% of float on a 3.14 short ratio means there is no squeeze fuel to cushion a break lower. Taiwan concentration remains a permanent tail risk that can gap the ADR independently of results, and the article pool in this bundle is four weeks stale and predates the print entirely.
A daily close below $407.13 - the October 15 earnings-day low - would confirm that the two-day stabilization has failed and reopen the 200-day at $390.20; a subsequent close below $382 would break the multi-year uptrend structure itself and should trigger a full exit regardless of the long-term franchise view. Conversely, the cautious near-term stance is invalidated by a daily close above $435.16 (the October 21 rejection high, just above the $433.58 50-day ) on above-average volume, which would re-establish the higher-low structure and restore the constructive six-month setup with $444.17 as the next objective.
Post-earnings de-rating risk is no longer theoretical: the September quarter beat by only 1.67% versus a 6.29% seven-quarter average, sequential growth decelerated to +6.73% from +23.5%, and the ADR at $424.37 is still 1.31% below its $430.00 pre-print close and 12.94% below its $487.47 high, so the market is pricing a materially higher bar into the January 14, 2027 guidance cycle 79 days away.
Technical distribution has not been reversed: TSM fell 4.53% on October 22 on 16.48 million shares (roughly 1.44x the 20-day average) while the October 23 and October 26 advances came on 9.48 and 9.51 million shares (0.83x average), price sits 2.12% below the 50-day of $433.58 and 4.46% below the 20-day of $444.17, the line printed a fresh series low at -5.965 with the signal at -2.095, and at 86.88 million remains 38.7% below the 141.65 million October 5 peak.
AI-complex contagion and volatility risk: the at 18.39 is inside the Neutral band but 20-day realized volatility is 33.05% and the is 2.99% of price, so a re-spike in volatility would extend de-risking in high-multiple AI leaders regardless of company results - while a rise in the 10-year yield from 4.986% back toward the 5.146% October 21 level would re-apply multiple pressure on a 27.50x trailing base.
Execution and capital-intensity risk: N2 ramp yields, advanced-packaging utilization and returns on the roughly $29.44B capacity approval plus the $100B Arizona program may undershoot, exposing substantial fixed-cost operating leverage while HBM, hybrid-bonding, glass-substrate and cooling specialists capture a larger share of AI value-chain economics, and incremental 2nm capacity remains unconfirmed on timing, size and node.
Geopolitical and data-integrity risk: essentially all leading-edge capacity is concentrated in Taiwan, creating cross-strait tail risk that no fundamental model captures and no stop can protect against on a gap, while the feed's $14.17T enterprise value, $4.017T cash, 0.445x price-to-sales, 3.923x and 54.66% FCF yield mix TWD-denominated statement values with a USD market cap and cannot serve as a valuation backstop.
Watch Next
Next earnings: Jan 14, 2027
The October 26 session is the single most market-moving item: TSM added 1.40% to $424.37 after October 23's 1.49% rebound, printed a $428.85 high that cleared the October 20 high of $428.21, and did so while the dropped 5.45% to 18.39 and the S&P 500, Nasdaq and Russell 2000 all advanced - the first broad-based risk-on tape in a week - yet total volume was only 9.51 million shares, 0.83x the 20-day average, so the move confirms a pause in AI-specific liquidation rather than a genuine institutional bid. The next real test is the $433.58 50-day on volume or a retest of $407.13; note that the article pool in this bundle is dated September 29 and predates the October 15 print by more than two weeks, so the freshest usable catalysts are the analyst actions in the revision feed and the October 15-26 price action rather than the article content.
Signal Dashboard
Decision inputs
6 signals
Fundamental
37.7%
Upside to analyst mean target
At $424.37 TSM trades at 27.50x trailing earnings (roughly $15.43 of implied trailing , consistent with the $3.14, $3.49, $4.31 and $4.60 quarters), 18.15x FY27 consensus of $23.38529 and 24.24x FY26 consensus of $17.50426, against a 0.7644 , 50.9% revenue growth and 68.7% earnings growth. The Zacks comparison in the supplied September 29 coverage posted 22.51x forward-12-month at $457.175 versus a 24.21x historical median; scaling for the 7.2% decline to $424.37 implies roughly 20.9x, still about 13.7% below the median, and the gap versus the feed's 18.15x is a basis difference (blended forward-12-month versus full FY27), with both readings below the historical median. On the feed's FY27 number, 18.15x for roughly 34% forward growth is a growth-adjusted multiple near 0.54x, comfortably cheap on a basis even before the 0.7644 three-to-five-year measure is applied. The feed's price-to-book of 80.99x and price-to-sales of 0.445x are not usable as value arguments: the sales, cash, debt, cash-flow and enterprise-value fields appear to be TWD-denominated statement values reported alongside a USD market cap, which is why the 'FCF yield' prints an impossible 54.66%, net cash to market cap prints 145.33% and the enterprise value of $14.17T runs at 6.44x the $2.20T market cap, making the 3.923x meaningless. The stale $363.95 GF Value from the September 29 coverage now sits 14.2% below the $424.37 close, so there is no dependable model-based floor. Net: fair value to modestly cheap on a growth-adjusted basis, with the October drawdown having improved the entry arithmetic versus the $487.47 high, but not a deep-value margin of safety.
Technical
Neutral
Trend quality
TSM closed at $424.37, about 4.46% below the 20-day of $444.17 and 2.12% below the 50-day of $433.58, but still 8.76% above the 200-day of $390.20. The ($444.17) > ($433.58) > ($390.20) golden-cross stack remains intact, so the long-term bull market is unbroken even as the intermediate trend stays broken after the October 22 failure. The last two sessions are the first consecutive gains since October 20-21: price undercut the October 19 and October 20 lows of $415.50 and $416.12 on October 23 with a $411.11 print and closed 92% of that day's range, then followed with a $428.85 intraday high on October 26 that edged above the October 20 high of $428.21 before settling at $424.37 - a marginally higher high to confirm the higher low. That is a short-term stabilization sequence, not a repair: the stock is still only $17.24 above the October 15 earnings-day low of $407.13, the October 21 rejection at $435.16 remains $10.79 overhead, and the 50-day at $433.58 is still flattening rather than rising. The stock is 12.94% below the $487.47 52-week high, 59.05% above the $266.82 low and at the 71.4% mark of its 52-week range: a confirming intermediate downtrend inside an intact long-term uptrend, with $390.20 as the line that separates repair from regime change.
Earnings
79d
Improving
The September 2026 quarter, reported October 15, delivered of $4.60 against a $4.52449 estimate, a beat of only 1.67%, the narrowest of the seven supplied quarters and well below the 6.29% average surprise; the ADR gapped from $430.00 to an intraday low of $407.13 before closing at $422.25 (-1.80%) on 22.45 million shares, slid to $412.61 (-2.28%) on October 16, recovered through $420.22, $425.08 and $431.89 into October 21, gave the entire rebound back on October 22 with a 4.53% decline to $412.35 on 16.48 million shares, then reversed intraday on October 23 off a $411.11 low and added a second gain on October 26 to close at $424.37 (+1.40%) on 9.51 million shares - leaving the stock still 1.31% below its $430.00 pre-print close despite a 57.5% year-over-year increase; the December-quarter consensus has nevertheless been revised UP to $5.1641 and the market's focus is squarely on N2 ramp margins and January guidance rather than the headline number.
News
Mixed-Bullish
Headline tone
The October 26 session is the single most market-moving item: TSM added 1.40% to $424.37 after October 23's 1.49% rebound, printed a $428.85 high that cleared the October 20 high of $428.21, and did so while the dropped 5.45% to 18.39 and the S&P 500, Nasdaq and Russell 2000 all advanced - the first broad-based risk-on tape in a week - yet total volume was only 9.51 million shares, 0.83x the 20-day average, so the move confirms a pause in AI-specific liquidation rather than a genuine institutional bid. The next real test is the $433.58 50-day on volume or a retest of $407.13; note that the article pool in this bundle is dated September 29 and predates the October 15 print by more than two weeks, so the freshest usable catalysts are the analyst actions in the revision feed and the October 15-26 price action rather than the article content.
Macro
Neutral
4.99% 10Y / 18.4 VIX
The at 18.39 after a 5.45% single-day decline is now 1.61 points above the bottom of the Risk-Off threshold rather than 0.55 points below it, and a broad tape (S&P 500 +0.70%, Nasdaq +0.82%, Russell 2000 +0.38%) with the 10-year at 4.986% is a supportive backdrop for holding a 1.239-beta, 33.05%-realized-volatility AI leader, but the Neutral band still argues for standard-to-reduced sizing rather than aggressive accumulation until price reclaims the 50-day .
Stability
High-Beta Growth
Core Growth
TSM is a franchise-grade High- Growth asset, not a speculative one: supplied coverage cites nearly 73% of the global foundry market in Q2 2026 versus 4% for UMC, and the feed shows a 65.85% gross margin, a 58.65% operating margin, a 73.04% margin, a 41.85% , a 2.51 current ratio, a 4.91x cash-to-debt ratio and seven consecutive supplied beats with zero downward revisions in any period over the trailing 30 days. Its Core Growth role is earned by the leading-edge technology position, the A14 roadmap running ahead of schedule, and FY27 consensus of $23.38529 versus $21.28402 ninety days ago. The risk being underwritten is real: a 1.239 beta, 33.05% 20-day realized volatility, an of 2.99% of price, essentially all leading-edge capacity concentrated in Taiwan, a 4.53% single-day decline on October 22, and a line that printed a fresh series low of -5.965 on October 26. With the shares 12.94% below the $487.47 high and 2.12% below the 50-day of $433.58, investors should expect recurring low-to-mid-teens drawdowns around earnings, AI-tape unwinds and macro shocks even with the multi-year franchise thesis intact.
Analyst Spread
Mean Target
$584.39
High / Low
$440 / $1000
Median Target
$557.50
Consensus range
$440 - $1000
— analysts
Mean
$440$584$1000
Consensus
The $584.39 mean target implies 37.7% upside from $424.37 and the $557.50 median implies 31.4%, while the $440 low target sits only 3.7% ABOVE spot - an unusual configuration in which even the most cautious published analyst is above the market price, consistent with targets lagging the selloff rather than signalling a fundamental gap-down. The $1000 high target implies 135.6% upside and the roughly $560 spread between low and high is genuine disagreement about the durability of the AI capacity cycle and the appropriate multiple; the number-of-analysts field is null, but the summary mix of 6 Strong Buy, 14 Buy and 1 Hold implies roughly 21 covering analysts, adequate breadth rather than thin coverage. The direction of travel matters more than the level: targets were raised at Barclays, Needham and Stifel within the last eight weeks with zero downgrades in 90 days, a materially better posture than the October 15-22 price action implied.
Positioning Pulse
Insider Signal
Neutral
Net Bias
Balanced
Insider Own.
0.0%
Institutional Own.
15.5%
Interpretation
Total disclosed value of roughly $346,000 is immaterial against a $2.20T market cap and transaction direction is unverifiable, so insider activity provides no actionable signal and should neither offset nor reinforce the fundamental case.
Notable activity
Five supplied records totaling roughly $346,428: Director Ursula M. Burns with 1,000 shares valued at $322,050, and Officer Bor-Zen Tien with 20, 17, 10 and 15 shares worth roughly $24,378 in aggregate across four filings ranging from $4,050 to $7,760. Transaction-type fields are blank and the dates are ordinal placeholders (0-4) rather than dates, and no sale rows appear, so direction cannot be confirmed from the feed.
Market Context
Industry
Semiconductors
Mixed-Bullish
Sentiment
31
Tracked names
13
Grouping
industry
Semiconductors industry is currently Mixed-Bullish with an average recommendation score near 55. capital and conviction are improving across the group, and leadership is concentrated in NVDA, AVGO, MU.
Rotation Drivers
Average recommendation deltas are trending higher across Semiconductors industry, which suggests improving risk appetite inside the group.
3 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bullish.
Leadership is concentrated in NVDA, AVGO, MU, so those names are the cleanest read on group-level capital rotation.
TSM is the foundry bottleneck for AI accelerators and custom silicon, and the September 29 coverage names Apple, Nvidia, AMD, Qualcomm, Google, Broadcom, Marvell, Amazon and OpenAI as advanced-node customers while JPMorgan argued the pullback made semiconductor valuations more attractive. The structural case keeps being reinforced by earnings revisions - FY27 consensus at $23.38529 versus $22.29861 a week ago and $21.28402 ninety days ago with zero downward revisions - but the equity expression is only beginning to repair: TSM is still 12.94% below its $487.47 high and 2.12% below its 50-day of $433.58, and at 86.88 million sits 38.7% below its October 5 peak even after two consecutive up days. The theme is intact at the earnings level and hostile at the multiple level, which is exactly the tug-of-war the current price reflects.
The October 22 AI-multiple unwind, followed by the October 23 and October 26 stabilization, is the immediate driver, and with the down to 18.39 and no company catalyst until January 14, the theme's near-term direction is being set by positioning flows rather than by demand data.
Broad-market risk appetite improved on October 26 with the S&P 500 +0.70%, the Nasdaq +0.82% and the Russell 2000 +0.38% while the fell 5.45% to 18.39, reversing the October 22 pattern in which the Nasdaq fell 2.60% and TSM dropped 4.53% on 1.44x average volume.
Analysts kept raising targets through the drawdown - Barclays to $670, DA Davidson maintaining $500, Needham to $560 - while FY27 estimates moved from $21.28402 ninety days ago to $23.38529, confirming the earnings case strengthens even as the multiple compresses.
The rate backdrop is a partial tailwind: the 10-year Treasury yield at 4.986% is 16 basis points below the 5.146% level reached on October 21, which mechanically supports long-duration AI multiples after the October 22-23 spike.
Leading-Edge Foundry and Advanced Packaging (N2/A14/CoWoS)
Score: 35
Mixed-Bullish
TSM is the direct listed leader in leading-edge foundry, with supplied coverage citing nearly 73% market share, broad N2 customer demand, A14 tape-outs ahead of schedule, and roughly $29.44B of approved capacity and advanced-packaging spending plus a $100B Arizona program and three N3 fabs across Taiwan, Arizona and Japan. The theme is structurally strengthening - Wells Fargo's report of a potential incremental 2nm expansion is read as an incremental positive for the whole equipment chain - but the economics only accrue if ramp yields and packaging utilization support returns, and the coverage explicitly notes HBM, hybrid bonding, glass-substrate and cooling specialists may capture a larger share of AI value-chain economics. The stock is 12.94% below its $487.47 high and 2.12% below its 50-day at $433.58, showing participants are reassessing execution and valuation risk rather than abandoning the theme.
Post-earnings digestion of N2 ramp costs, the unconfirmed incremental 2nm capacity report, and the October 23-26 recovery off $411.11 are the immediate swing factors for both TSM and the semiconductor equipment chain.
The roughly $29.44B capacity and advanced-packaging approval, three N3 fabs across Taiwan, Arizona and Japan, conversion of 5nm tools to N3, and the ASML collaboration on larger-format EUV photomasks reinforce a multi-year leading-edge capex cycle across equipment and materials suppliers.
A14 pre-production is slated for 2027 and volume production for 2028 with tape-outs ahead of schedule, but N2 margin dilution and unconfirmed incremental 2nm plans temper the near-term payoff, and the absence of volume on the October 23 and October 26 advances (0.83x the 20-day average) is a live counter-signal.
Key Stats
23 metrics total
Market Cap
$2.20T
P/E (TTM)
27.5
Forward P/E
18.1
Revenue Growth
50.9%
ROE
41.9%
Beta
1.24
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
0.4
Price / Book
81.0
EV / EBITDA
3.9
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
65.8%
Operating Margin
58.7%
Debt / Equity
11.6
Current Ratio
2.51x
Quick Ratio
2.29x
Positioning & Range
Short interest and 52-week location.
Short % Float
0.6%
Short Ratio
3.14x
52W High
$487.47
52W Low
$266.82
From 52W High
-12.9%
From 52W Low
59.0%
Company Classification
Sector and industry context.
Sector
Technology
Industry
Semiconductors
Additional Signals
Free Cash Flow
$1203071877120.00
Detailed Analysis
Valuation
At $424.37 TSM trades at 27.50x trailing earnings (roughly $15.43 of implied trailing , consistent with the $3.14, $3.49, $4.31 and $4.60 quarters), 18.15x FY27 consensus of $23.38529 and 24.24x FY26 consensus of $17.50426, against a 0.7644 , 50.9% revenue growth and 68.7% earnings growth. The Zacks comparison in the supplied September 29 coverage posted 22.51x forward-12-month at $457.175 versus a 24.21x historical median; scaling for the 7.2% decline to $424.37 implies roughly 20.9x, still about 13.7% below the median, and the gap versus the feed's 18.15x is a basis difference (blended forward-12-month versus full FY27), with both readings below the historical median. On the feed's FY27 number, 18.15x for roughly 34% forward growth is a growth-adjusted multiple near 0.54x, comfortably cheap on a basis even before the 0.7644 three-to-five-year measure is applied. The feed's price-to-book of 80.99x and price-to-sales of 0.445x are not usable as value arguments: the sales, cash, debt, cash-flow and enterprise-value fields appear to be TWD-denominated statement values reported alongside a USD market cap, which is why the 'FCF yield' prints an impossible 54.66%, net cash to market cap prints 145.33% and the enterprise value of $14.17T runs at 6.44x the $2.20T market cap, making the 3.923x meaningless. The stale $363.95 GF Value from the September 29 coverage now sits 14.2% below the $424.37 close, so there is no dependable model-based floor. Net: fair value to modestly cheap on a growth-adjusted basis, with the October drawdown having improved the entry arithmetic versus the $487.47 high, but not a deep-value margin of safety.
Balance Sheet
The reported 11.62 debt-to-equity figure reads as percentage-scaled (11.62%) rather than 11.6x levered, and it is corroborated by a 4.91x cash-to-debt ratio, a 3.82x operating-cash-flow-to-debt ratio, a 2.51 current ratio and a 2.29 quick ratio - all consistent with a cash-generative, investment-grade balance sheet that is nowhere near the binding constraint on this thesis. The feed's $4.017T total cash against $0.818T total debt is directionally a large net-cash position, and the derived net-cash-to-market-cap ratio of 145.33% is magnitude-contaminated by the currency mismatch, but the ratio evidence is internally consistent and reliable even when the absolute values are not. A 41.85% paired with a 20.58% confirms returns are generated by operating excellence rather than leverage, and the balance sheet can fund the Arizona and N2 build without straining liquidity.
Growth
Revenue growth of 50.9% and earnings growth of 68.7% remain exceptional for a company of this size. Supplied quarterly has climbed without interruption from $2.12 (March 2025) through $2.47, $2.92, $3.14, $3.49 and $4.31 to $4.60, a 57.5% year-over-year increase in the September 2026 quarter, but sequential growth decelerated to +6.73% from +23.5% in the June 2026 quarter. Consensus models FY26 of $17.50426 (roughly +64% versus the $10.65 sum of the four 2025 quarters as supplied) and FY27 of $23.38529 (roughly +34% year over year), and both have been revised up with FY27 up 4.87% in seven days and 9.87% in ninety days. Management expects leading-edge demand plus cost improvements to offset the steep N2 ramp, but the 1.67% September surprise was the narrowest of the seven supplied quarters, showing consensus has largely caught up to that ramp and the burden of proof now sits on January guidance.
Business Quality
Leading-edge foundry is one of the highest-barrier businesses in the global economy and TSM's numbers reflect it: a 65.85% gross margin, a 58.65% operating margin, a 73.04% margin and a 51.12% net margin, with of 41.85% and of 20.58%. Supplied coverage cites nearly 73% of the global foundry market in Q2 2026 versus 4% for UMC, and current and quick ratios of 2.51 and 2.29 provide a genuine liquidity buffer. Insider ownership of about 0.01% and institutional ownership of 15.51% reflect the ADR structure rather than a governance flaw. The two quality caveats are concentration of revenue in a handful of leading-edge customers (Apple, Nvidia, AMD, Qualcomm, Google, Broadcom, Marvell, Amazon and OpenAI are all named in the supplied coverage) and the fact that essentially all leading-edge capacity sits in Taiwan, which is a permanent structural discount no margin line offsets.
Capital Allocation
Management is deploying aggressively: roughly $29.44B approved for capacity, advanced packaging and construction, an additional $100B Arizona program, three N3 fabs across Taiwan, Arizona and Japan, conversion of 5nm tools to N3 in Taiwan, and an ASML collaboration on larger-format EUV photomasks intended to raise fab productivity, cut cost per die and remove stitching constraints. These commitments defend the technology lead and add geographic redundancy but raise fixed-cost operating leverage if demand, yields or packaging utilization disappoint, and the supplied coverage notes that HBM, hybrid-bonding, glass-substrate and advanced-cooling specialists may capture a growing share of AI value-chain economics. The feed lists 5.186B shares outstanding, a 0.90% dividend yield and a 24.46% payout ratio, but provides no share-count history or buyback data, so dilution cannot be assessed; with the cash-flow fields currency-contaminated, the exact degree of internal funding of the capex program also cannot be confirmed from this bundle.
Estimate Revisions
Revision momentum remains uniformly positive through a third consecutive week of drawdown-and-recovery price action, confirming rather than newly accelerating: over the last 30 days there were zero downward revisions in any of the four periods and 2-3 upward revisions in each, with FY26 at $17.50426 (7 days ago $17.03445, +2.76%; 30 days ago $16.92658; 90 days ago $16.69542, +4.85%) and FY27 at $23.38529 (7 days ago $22.29861, +4.87%; 30 days ago $21.91887; 90 days ago $21.28402, +9.87%). The current-quarter estimate sits at $5.1641 versus $5.04936 seven days ago and $4.9585 ninety days ago (+4.15%), and next-quarter at $5.19402 versus $5.05694 (+2.71%) and $4.89148 ninety days ago (+6.18%). Sell-side actions confirm the direction: Barclays raised its target to $670 from $665 on October 16, DA Davidson maintained Buy with a $500 target the same day, Needham raised to $560 from $530 on October 15, and Barclays had already moved to $665 from $650 on October 6 after Stifel initiated at Buy with $515 on September 2, with zero downgrades recorded in the last 90 days and the rating mix improving to 6 Strong Buy / 14 Buy / 1 Hold from 6/12/1 two months ago. The caveat is that the September-quarter beat was only 1.67% against a 6.29% seven-quarter average, so the bar into the January 14 print is measurably higher even as the estimates keep climbing.